Australia's ResMed slips after rival Apnimed posts positive clinical trial results

ResMed

20/05/2025 06:45

** ASX-listed shares of medical device-maker ResMed RMD.AX fall as much as 7.3% to A$36.02, their lowest level since April 24

** Stock of co, which is involved in treating sleep apnea, COPD and other chronic diseases, marks biggest intraday pct loss since March 12

** RMD is the top pct loser on the ASX 200 benchmark

** Rival Apnimed, which is unlisted, announced positive topline results in first phase 3 clinical trial of AD109, an oral pill for obstructive sleep apnea

** Stock up 0.6% YTD

 (Reporting by Sneha Kumar in Bengaluru)

 ((Sneha.kumar@thomsonreuters.com;))